Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 6/20 | 0.34 |
| ▸ | CES1 | P23141 | 4/20 | 0.34 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 3/20 | 0.32 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5421564 | 0.83 | CES2 (0.49) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL5403754 | 0.80 | CES2 (0.45) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL5403727 | 0.77 | CES2 (0.43) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL5407498 | 0.76 | CES2 (0.37) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL6269037 | 0.74 | CES2 (0.47) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL5408005 | 0.74 | ASAH1 (0.38) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL5944377 | 0.73 | CES2 (0.49) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL5407492 | 0.71 | CES2 (0.53) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL6263282 | 0.70 | CES2 (0.51) | CES2MAPTGMNNTP53POLB | |
| SCHEMBL6266157 | 0.70 | CES2 (0.45) | CES2MAPTGMNNTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253296-B2 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2007-08-07 | — | — | US | disclosed |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | GENFIT (FR) | 2006-07-13 | — | — | US | disclosed |
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | GENFIT (FR) | 2006-03-30 | — | — | US | disclosed |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | GENTIF (FR) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069156-A1 | Acylated aminopropanediols and analogues and therapeutic uses thereof | AASDHPPT, ABAT, AADAC | CES2 944/4885MAPT 1263/4885GMNN 2989/4885 |
| US-20060035977-A1 | Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f | ASS1, SMURF1, SMURF2 | CES2 1728/4885MAPT 3940/4885GMNN 2879/4885 |
| US-20060154984-A1 | Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof | AGPAT5, HAGH, AGPAT2 | CES2 1234/4885MAPT 725/4885GMNN 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.